Back to Treatments

Treatment

Nivolumab + Ipilimumab

3
Conditions
139
Trials
14K
Participants
33%
Average Safety

Condition Evidence

Kidney cancer

96 trials · 550 participants

85% effectiveness · 35% safety

Malignant skin melanoma

25 trials · 5,500 participants

93% effectiveness · 30% safety

Mesothelioma

18 trials · 8,000 participants

75% effectiveness · 35% safety
Nivolumab + Ipilimumab | DFDA